World Conservation Organization

Members of the World Health Organization (WHO) agreed with the text of a legally compulsory contract intended for better resolving future pandemics.

The Pact is designed to avoid disorganization and competition for the resources observed during the COVID-19 outbreak.

Key elements include rapid data sharing about new diseases to provide scientists and pharmaceutical companies to develop therapies and vaccines.

For the first time, the WHO will also review global supplies for masks, medical bathrobe and other personal protective equipment (PPE).

WHO D -CEO D -R Tedroz Hamon Gebreiez called this deal as “a significant milestone in our common path to a safer world.”

“(Member States) also demonstrated that multibarism is alive and healthy, and that in our divided world the nation can still work together to find common ground, and the general response to common threats,” he said.

The legally compulsory pact, which reached early on Wednesday, took place after three years of negotiations between the member states.

And only for the second time in the 75-year history of the WHO was reached an international agreement of this type-the first one was a deal to fight tobacco in 2003.

It should still be officially accepted by members when they are found in the World Health Assembly next month.

US talks were not part of the final discussions after President Donald Trump announced his decision to leave the Global Health Agency, and the US would not be linked to the Covenant if he would leave in 2026.

According to the agreed conditions, countries will have to guarantee that pandemic drugs will be available worldwide in the future outbreak.

The manufacturers involved will have to allocate 20% of the production of vaccines, therapeutic drugs and the diagnosis of WHO. At least 10% will need to donate the rest at affordable prices.

Countries also approved the transfer of healthcare technology to poor countries while it was “mutually agreed”.

This should also provide more local vaccines and medicines during a pandemic. But this item was extremely controversial.

Educational countries are still angry with the wealthy peoples bought and taken by vaccines during COVID-19, while countries with large pharmaceutical industries are undergoing mandatory transfers can blow research and development.

The agreement is based on the proposed access system to pathogens and payments (PABS), which allows for a faster exchange of data between pharmaceutical companies.

This should allow those firms to start working on new drugs in any future outbreak.